GlobeNewsWire
03 Sept 2026, 05:30 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
ONWARD Medical has performed the first implant in the EIGER clinical feasibility study to evaluate the ARC-IM System for restoring mobility after spinal cord injury. — The start of a human clinical trial for a new indication is a major de-risking milestone for a medtech company's pipeline.
+0.40The EIGER study results are intended to inform the design of a future pivotal study required for market authorization. — This defines the regulatory pathway to commercialization, though it remains in the early feasibility stage.
+0.20The ARC-IM System is simultaneously being evaluated in the Empower BP global pivotal study for blood pressure instability. — Diversification across multiple indications (mobility and blood pressure) increases the overall probability of platform success.
+0.10Which stocks this story touches
Continue reading
6 related stories
Search tags
The company announced the first implant in a new clinical feasibility study to restore mobility after spinal cord injury.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
5h ago
